US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Relief Therapeutics Hldg
(OP:
RLFTF
)
0.2655
UNCHANGED
Last Price
Updated: 2:52 PM EDT, Aug 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Relief Therapeutics Hldg
< Previous
1
2
3
4
5
6
7
Next >
Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI(TM) (aviptadil) in NIH Sponsored ACTIV-3 Study in Patients with Life-Threatening COVID-19
August 19, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / August 19, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics' Lead Candidate Gets US Orphan Drug Tag In Sarcoidosis
↗
August 03, 2021
The FDA has granted Orphan Drug Designation to Relief Therapeutics Holding AG's (OTC: RLFTF) for RLF-100 (aviptadil), an inhaled formulation, for...
Via
Benzinga
Relief Announces Receipt of U.S. FDA Orphan Drug Designation for the use of RLF-100 (aviptadil) in the Treatment of Sarcoidosis
August 03, 2021
From
RELIEF THERAPEUTICS Holding AG
Via
Business Wire
Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia
July 28, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / July 28, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief and AdVita Close Definitive Agreement for Relief to Acquire All Outstanding Shares of AdVita
July 28, 2021
Acquisition Expands Scope of Development of Inhaled Formulation of Aviptadil GENEVA, SWITZERLAND / ACCESSWIRE / July 28, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief "), a...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Relief Therapeutics Announces CHF 15 Million Private Placement
July 26, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / July 26, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Why NRX Pharmaceuticals (NRXP) Stock Is Moving Friday?
↗
July 23, 2021
Extending yesterday's gain, NRx Pharmaceuticals Inc (NASDAQ: NRXP) stock is up more than 26% during the premarket trading on Friday. NRx's stock opened Thursday...
Via
Benzinga
Relief Reports that its U.S. Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil
July 23, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / July 23, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting
July 22, 2021
Shares being used in part for payments related to AdVita and APR acquisitions Acquisitions are part of Relief's transformation into a fully integrated diversified commercial-stage pharmaceutical...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Relief Reports that its U.S. Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19
July 20, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / July 20, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial
July 13, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / July 13, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR
June 29, 2021
Transforms Relief into a fully integrated commercial-stage biopharmaceutical company Acquisition further diversifies Relief's pipeline with both commercial products and clinical-stage programs and...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large Majority
June 21, 2021
GENEVA, SWITZERLAND / June 21, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil)...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19
June 16, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / June 16, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration
June 02, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / June 2, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in...
From
Relief Therapeutics Holdings AG
Via
AccessWire
NRx Files for Zyesami Emergency Use in Critical COVID-19 Patients With Respiratory Failure
↗
June 01, 2021
NRx Pharmaceuticals (NASDAQ: NRXP) has applied with FDA requesting Emergency Use Authorization (EUA) for Zyesami (Aviptadil-acetate) for critically ill COVID-19...
Via
Benzinga
Relief Appoints Dr. Taneli Jouhikainen as Chief Operating Officer
May 28, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / May 28, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG
May 27, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / May 27, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle Disorders
May 18, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / May 18, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF)("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray
May 17, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / May 17, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF)("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Review Of Present Therapies For Covid-19
↗
May 09, 2021
A summary of authorized drugs for Covid-19, those in development, and those that have failed.
Via
Talk Markets
Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR
May 04, 2021
Acquisition would further diversify Relief's pipeline with both commercial products and clinical-stage programs GENEVA and BALERNA, SWITZERLAND / ACCESSWIRE / May 4, 2021 / RELIEF THERAPEUTICS Holding...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome
April 22, 2021
Investigator-sponsored trial being conducted at major medical centers in Switzerland Relief provides update on RLF-100 clinical development in Europe GENEVA, SWITZERLAND, and GUNDELFINGEN, GERMANY /...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp.
April 19, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / April 19, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), commented today on certain statements made by NeuroRx, Inc., its...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports 2020 Financial Results and Provides Business Update
April 15, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / April 15, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Engages Jan-Jaap Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant
April 07, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / April 7, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM...
From
Relief Therapeutics Holdings AG
Via
AccessWire
< Previous
1
2
3
4
5
6
7
Next >
